Review
Biochemistry & Molecular Biology
Mariusz Dabrowski
Summary: Cancer has become the leading cause of death in the European Union population under 65 in the last decade, with diabetes considered as a factor increasing cancer risk. Antidiabetic medications can affect cancer risk through various mechanisms, with some medications having beneficial effects while others may potentially be harmful. The use of inhibitors of the sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes treatment and their association with cancer risk requires further investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Kunika Saini, Smriti Sharma, Yousuf Khan
Summary: DPP-4 inhibition is a promising therapy for Type 2 Diabetes Mellitus (T2DM) that promotes the incretin effect. This review discusses the modes of action, clinical efficiency, safety profiles, and future directions of DPP-4 inhibitors, including their potential application in managing COVID-19 patients. The authors conclude that DPP-4 inhibitors are justified due to their ability to control blood glucose levels and manage diabetes-related risk factors.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Vishal Mathur, Ozair Alam, Nadeem Siddiqui, Mukund Jha, Ajay Manaithiya, Sandhya Bawa, Naveen Sharma, Sultan Alshehri, Prawez Alam, Faiyaz Shakeel
Summary: This article discusses various scaffolds that can be used to develop DPP-4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). The study highlights different scaffolds with high DPP-4 inhibition activity and explains the potential enhancement by substituting certain atoms. Docking experiments were performed on existing drugs and their interaction with specific residues was studied. The article also describes the synthesis schemes for commercially available DPP-4 inhibitors. Overall, the use of halogenated scaffolds for developing DPP-4 inhibitors is an area of increasing interest.
Article
Multidisciplinary Sciences
Sanghwa Park, Jiseon Jeong, Yunna Woo, Yeo Jin Choi, Sooyoung Shin
Summary: This cohort study using Korean health insurance data found that DPP-4 inhibitors were not associated with an increased risk of infections in type 2 diabetes patients receiving insulin treatment, while SGLT-2 inhibitors were found to be associated with a higher risk of genital infections. No increased risk of urinary tract infections was observed with SGLT-2 inhibitors compared to metformin.
SCIENTIFIC REPORTS
(2023)
Review
Immunology
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Susana Nogueira Diniz, Andrea Fabbri, Marco Infante
Summary: Current research suggests that combination therapy with vitamin D and DPP-4 inhibitors may play a potential role in preserving beta-cell function in autoimmune diabetes. The aim of these therapies is to counteract autoimmune responses and slow down the progression of diabetes.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Katarina Tomovic, Budimir S. Ilic, Andrija Smelcerovic
Summary: This study classifies approved and potent DPP-4 inhibitors with gliptin-like structures into three groups based on their structures and mechanisms of inhibition, showing different binding modes in various domains of the enzyme. The analysis of structure-activity relationship and protein-ligand interaction fingerprints provides insights for the design strategies of DPP-4 inhibitors.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Endocrinology & Metabolism
Andre J. Scheen
Summary: DPP-4 inhibitors and SGLT2 inhibitors provide new options for oral management of type 2 diabetes in the elderly, with similar glucose-lowering efficacy but potentially different tolerance and safety profiles, favoring DPP-4 inhibitors.
DIABETES & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Summary: This study conducted a trial-level meta-analysis and found that the combination of SGLT2i and DPP4i in the treatment of type 2 diabetes may have similar cardiovascular and renal benefits. This finding is of great significance in filling the existing knowledge gap.
ENDOCRINE PRACTICE
(2023)
Article
Pharmacology & Pharmacy
Shashank Joshi, Vathsala Jayanth, Subramanian Loganathan, Vasan K. Sambandamurthy, Sandeep N. Athalye
Summary: Insulin therapy is crucial for glycemic control in diabetes patients, and oral insulin offers a convenient and potentially safer option compared to injections. Insulin tregopil (IN-105) is an ultra-fast onset short-acting oral insulin analog with a good safety profile and better post-prandial glucose control in early post-meal period compared to an active comparator.
Review
Biochemistry & Molecular Biology
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Summary: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) globally. Dipeptidyl peptidase (DPP)-4 inhibitors are commonly used in treating patients with type 2 diabetes (T2D) by reducing glucose levels through inhibition of incretin degradation. Clinical and experimental studies have shown that DPP-4 inhibitors have beneficial effects on DKD, independent of their glucose-lowering abilities, mediated by anti-fibrotic, anti-inflammatory, and anti-oxidative stress properties.
Review
Biochemistry & Molecular Biology
Nhung Thi Phuong Nong, Jue-Liang Hsu
Summary: This review discusses the promising therapeutic strategies for managing type 2 diabetes, focusing on the inhibition of DPP-IV, PTP-1B, and alpha-glucosidase enzymes. Various food protein-derived antidiabetic bioactive peptides have been isolated and verified, showing potential for preventing and managing diabetes. Clinical studies are needed to validate the efficiency of these bioactive peptides before commercial applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, Research & Experimental
Kai-Wen Zhang, Si-Yu Liu, Yuan Jia, Ming-Li Zou, Ying-Ying Teng, Zhong-Hua Chen, Yueyue Li, Danyang Guo, Jun-Jie Wu, Zheng-Dong Yuan, Feng-Lai Yuan
Summary: This paper introduces the wound healing process and the effects of DPP-4/CD26 on cells involved in different stages of wound healing. It discusses the potential of DPP-4/CD26 as a therapeutic target for promoting wound healing and inhibiting scar formation.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cardiac & Cardiovascular Systems
Mei-zhen Wu, Tiew-Hwa Katherine Teng, Christopher Tze-Wei Tsang, Yap-Hang Chan, Chi-Ho Lee, Qing-wen Ren, Jia-Yi Huang, Iok-fai Cheang, Yi-Kei Tse, Xin-li Li, Xin Xu, Hung-Fat Tse, Carolyn S. P. Lam, Kai-Hang Yiu
Summary: Our study provides real-world evidence that compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with lower risk of hyperkalaemia and did not increase the incidence of hypokalaemia in patients with T2DM.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Oncology
Rui Li, Xin Zeng, Meihua Yang, Jinmei Feng, Xiaohui Xu, Liming Bao, Tingbo Ye, Xin Wang, Bingqian Xue, Yi Huang
Summary: The study found that the antidiabetic drug DPP-4i interacts with breast cancer cells through the ROS-NRF2-HO-1-NF-kappa B-NLRP3 axis to promote murine breast cancer metastasis. The research revealed the mechanism of DPP-4i in breast cancer progression and provided new insights for improving the tumor microenvironment to alleviate DPP-4i-induced breast cancer metastasis.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Milosz Knura, Wojciech Garczorz, Adam Borek, Franciszek Drzymala, Krystian Rachwal, Kurian George, Tomasz Francuz
Summary: The incidence of prostate cancer (PC) and diabetes is on the rise, especially with aging. While diabetes is inversely correlated with the incidence of prostate cancer, it increases mortality in various cancer types. Current treatment for diabetes involves lifestyle changes and medication management, with consideration for comorbidities. Specific anti-diabetic drugs may have potential benefits for the treatment of prostate cancer.
Article
Endocrinology & Metabolism
Robert Wagner, Liisa H. Hakaste, Emma Ahlqvist, Martin Heni, Juergen Machann, Fritz Schick, Emmanuel Van Obberghen, Norbert Stefan, Baptist Gallwitz, Tiinamaija Tuomi, Hans-Ulrich Haering, Leif Groop, Andreas Fritsche
Article
Endocrinology & Metabolism
Francisco J. Tinahones, Baptist Gallwitz, Matias Nordaby, Sophia Goetz, Mario Maldonado-Lutomirsky, Hans J. Woerle, Uli C. Broedl
DIABETES OBESITY & METABOLISM
(2017)
Article
Endocrinology & Metabolism
Philip D. Home, Raymond L. H. Lam, Wendy L. Carofano, Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, Michael C. Marcos, Julio Rosenstock, Priscilla A. Hollander, Baptist Gallwitz
DIABETES OBESITY & METABOLISM
(2018)
Article
Endocrinology & Metabolism
Priscilla A. Hollander, Wendy L. Carofano, Raymond L. H. Lam, Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, Michael C. Marcos, Marc S. Rendell, Philip D. Home, Baptist Gallwitz, Julio Rosenstock
DIABETES OBESITY & METABOLISM
(2018)
Article
Endocrinology & Metabolism
Dorothea Reichert, Nikolaus Scheper, Dirk Mueller-Wieland, Dennis Haeckl, Andreas Bayer, Michael Horst, Baptist Gallwitz
DIABETOLOGIE UND STOFFWECHSEL
(2018)
Article
Medicine, General & Internal
B. Gallwitz, A. Neu
Article
Endocrinology & Metabolism
Ruediger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans-Georg Joost, Harald Klein, Dirk Mueller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Stephan Schreiber, Erhard Siegel
DIABETOLOGIE UND STOFFWECHSEL
(2018)
Editorial Material
Endocrinology & Metabolism
Ruediger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans-Georg Joost, Harald Klein, Dirk Mueller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Stephan Schreiber, Erhard Siegel
Article
Endocrinology & Metabolism
Ruediger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Mueller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Erhard Siegel
DIABETOLOGIE UND STOFFWECHSEL
(2019)
Article
Endocrinology & Metabolism
Ruediger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Mueller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Erhard Siegel
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
(2019)
Editorial Material
Endocrinology & Metabolism
Ruediger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kelleree, Harald Klein, Dirk Mueller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Erhard Siegel
Article
Cardiac & Cardiovascular Systems
Baptist Gallwitz
AKTUELLE KARDIOLOGIE
(2018)
Article
Endocrinology & Metabolism
Ronald C. W. Ma, Stefano Del Prato, Baptist Gallwitz, Vyankatesh K. Shivane, Diane Lewis-D'Agostino, Zelie Bailes, Sanjay Patel, Jisoo Lee, Maximilian von Eynatten, Maximiliano Di Domenico, Stuart A. Ross
JOURNAL OF DIABETES INVESTIGATION
(2018)
Article
Endocrinology & Metabolism
Baptist Gallwitz, Samuel Dagogo-Jack, Vivian Thieu, Luis-Emilio Garcia-Perez, Imre Pavo, Maria Yu, Kenneth E. Robertson, Nan Zhang, Francesco Giorgino
DIABETES OBESITY & METABOLISM
(2018)